Stocks
ICU Medical Financial Statements (ICUI) |
||||||||||
| ICU Medicalsmart-lab.ru | % | 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 09.05.2023 | 07.08.2023 | 06.11.2023 | 27.02.2024 | 07.05.2024 | 07.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 568.6 | 549.3 | 553.3 | 588.0 | 566.0 | 2 257 | |||
| Operating Income, bln rub | 19.4 | 2.76 | 22.9 | -19.2 | 3.77 | 10.2 | ||||
| EBITDA, bln rub | ? | 75.2 | 75.1 | 68.8 | 37.9 | 59.3 | 241.1 | |||
| Net profit, bln rub | ? | -9.81 | -9.93 | 7.24 | -17.1 | -39.5 | -59.3 | |||
| OCF, bln rub | ? | 41.2 | -1.47 | 35.2 | 91.3 | 45.8 | 170.7 | |||
| CAPEX, bln rub | ? | 16.7 | 20.4 | 24.6 | 32.0 | 18.9 | 95.8 | |||
| FCF, bln rub | ? | 24.5 | -21.9 | 10.6 | 59.3 | 26.9 | 74.9 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 172.3 | 173.2 | 169.5 | 177.0 | 179.5 | 699.2 | ||||
| Cost of production, bln rub | 376.6 | 357.0 | 369.4 | 430.2 | 382.7 | 1 539 | ||||
| R&D, bln rub | 19.8 | 22.3 | 20.9 | 22.4 | 21.8 | 87.4 | ||||
| Interest expenses, bln rub | 22.5 | 24.1 | 24.2 | 33.0 | 26.4 | 107.8 | ||||
| Assets, bln rub | 4 471 | 4 463 | 4 377 | 4 378 | 4 288 | 4 288 | ||||
| Net Assets, bln rub | ? | 2 100 | 2 115 | 2 098 | 2 123 | 2 068 | 2 068 | |||
| Debt, bln rub | 1 647 | 1 641 | 1 635 | 1 705 | 1 687 | 1 687 | ||||
| Cash, bln rub | 224.2 | 197.7 | 199.0 | 254.7 | 251.4 | 251.4 | ||||
| Net debt, bln rub | 1 423 | 1 443 | 1 436 | 1 450 | 1 436 | 1 436 | ||||
| Ordinary share price, rub | 165.0 | 178.2 | 119.0 | 99.7 | 107.3 | 100.1 | ||||
| Number of ordinary shares, mln | 24.0 | 24.1 | 24.1 | 24.1 | 24.2 | 24.2 | ||||
| Market cap, bln rub | 3 961 | 4 290 | 2 872 | 2 408 | 2 600 | 2 424 | ||||
| EV, bln rub | ? | 5 384 | 5 733 | 4 308 | 3 858 | 4 035 | 3 860 | |||
| Book value, bln rub | -320 | -279 | -237 | -220 | -228 | -228 | ||||
| EPS, rub | ? | -0.41 | -0.41 | 0.30 | -0.71 | -1.63 | -2.45 | |||
| FCF/share, rub | 1.02 | -0.91 | 0.44 | 2.46 | 1.11 | 3.09 | ||||
| BV/share, rub | -13.3 | -11.6 | -9.84 | -9.10 | -9.43 | -9.43 | ||||
| EBITDA margin, % | ? | 13.2% | 13.7% | 12.4% | 6.45% | 10.5% | 10.7% | |||
| Net margin, % | ? | -1.73% | -1.81% | 1.31% | -2.92% | -6.97% | -2.63% | |||
| FCF yield, % | ? | -2.77% | -1.02% | -0.44% | 3.01% | 2.88% | 3.09% | |||
| ROE, % | ? | -2.19% | -2.29% | -1.34% | -1.40% | -2.87% | -2.87% | |||
| ROA, % | ? | -1.03% | -1.09% | -0.64% | -0.68% | -1.38% | -1.38% | |||
| P/E | ? | -86.1 | -88.5 | -102.4 | -81.2 | -43.8 | -40.9 | |||
| P/FCF | -36.1 | -98.3 | -229.2 | 33.2 | 34.7 | 32.3 | ||||
| P/S | ? | 1.72 | 1.87 | 1.28 | 1.07 | 1.15 | 1.07 | |||
| P/BV | ? | -12.4 | -15.3 | -12.1 | -11.0 | -11.4 | -10.6 | |||
| EV/EBITDA | ? | 39.3 | 25.3 | 19.0 | 15.0 | 16.7 | 16.0 | |||
| Debt/EBITDA | 10.4 | 6.37 | 6.34 | 5.64 | 5.95 | 5.95 | ||||
| R&D/CAPEX, % | 118.1% | 109.3% | 85.0% | 70.1% | 115.8% | 91.3% | ||||
| CAPEX/Revenue, % | 2.94% | 3.71% | 4.44% | 5.44% | 3.33% | 4.25% | ||||
| ICU Medical shareholders | ||||||||||
